You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Glenmark Pharma says no significant clinical benefit with Umifenovir

Capital Market 

Glenmark Pharmaceuticals announced results of its "FAITH" combination trial with antivirals umifenovir and favipiravir for the treatment of moderate hospitalized COVID-19 patients.

The announcement was made after market hours on Friday, 9 October 2020. Shares of Glenmark Pharmaceuticals fell 1.59% to settle at Rs 492 on Friday.

Glenmark Pharmaceuticals on Friday announced results of its FAITH combination trial with antivirals Umifenovir and Favipiravir for the treatment of moderate hospitalized COVID-19 patients. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir.

This second study titled the FAITH trial evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy. As per the results that Glenmark today presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir. The FAITH study enrolled a total of 158 hospitalized patients with moderate COVID-19 in India.

In June 2020, Glenmark became the first company in India to receive manufacturing and marketing approval for FabiFlu as part of accelerated approval process, considering the emergency situation of the COVID-19 outbreak in the country. Glenmark successfully developed the active pharmaceutical ingredient (API) and the formulation for the oral antiviral through its own in-house R&D team.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, October 12 2020. 08:41 IST